Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefoperazone-sulbactam 3:1 vs 2:1 for respiratory and urinary infections
CTR20130998Phase 2Active
- Sponsor
- Xiangbei Welman Pharmaceuticals
- Start
- Mar 2014
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cefoperazone + sulbactam in acute lower respiratory tract infection (LRTI), Acute Urinary Tract Infection (UTI), bacterial disease, sponsored by Xiangbei Welman Pharmaceuticals. Started Mar 2014; status: active.
02
Drugs
cefoperazone + sulbactam
03
Conditions
acute lower respiratory tract infection (LRTI)Acute Urinary Tract Infection (UTI)bacterial disease
Beyond the preview
Go deeper on CTR20130998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20130998.